TCR Library Program

About Medigene

Medigene is a clinical-stage biotech focused on engineering T-cell receptor (TCR)-modified T-cell therapies for solid tumors, a notoriously difficult-to-treat area. Its strategy is built on two proprietary technology pillars: a high-throughput TCR discovery platform and a PD1-41BB costimulatory switch receptor designed to enhance T-cell persistence and function. The company has advanced its lead candidate, MDG1011, into Phase I/II clinical trials and is actively building a pipeline of novel TCRs through internal discovery and partnerships. As a publicly traded entity, Medigene aims to validate its platform and establish a leadership position in the evolving TCR-T cell therapy landscape.

Therapeutic Areas

Other Various Solid Tumors Drugs